

## AMENDMENTS TO THE CLAIMS

The following listing of claims will replace all prior versions and listings thereof:

1. (Currently Amended) ~~Use of the~~A pharmaceutical composition comprising Annexin V protein or an N-terminal fragment of Annexin V, ~~optionally in the form of or a corresponding salt thereof, in the manufacture of a pharmaceutical composition to prevent atherothrombosis and/or plaque rupture.~~
2. (Canceled)
3. (Currently Amended) ~~The use according to claim 1 or claim 2~~The method of claim 4, wherein the effective amount of the Annexin V in the pharmaceutical composition is determined from a diagnostic status analysis of ~~the~~ Annexin V-endothelium binding in said subject.
4. (Currently amended) A method of treating a subject at risk of atherothrombosis and/or plaque rupture~~[[,]]~~ comprising administering to said subject a pharmaceutical composition comprising an effective amount of Annexin V or N-terminal fragment of Annexin V or ~~its~~a corresponding salt thereof.
5. (Currently amended) ~~[[A]]~~The method according to claim 4, where~~wherein~~in the subject at risk is a systemic lupus erythematosus (SLE) patient.
6. (Currently amended) ~~Use of~~A pharmaceutical composition comprising a purified subfraction of pooled immunoglobulins with the capacity to inhibit antibodies binding to Annexin V, or a purified subfraction of pooled immunoglobulins with the capacity to promote binding of Annexin V to endothelium, ~~in the manufacturing of a medicament to prevent atherothrombosis and/or plaque rupture.~~
7. (Canceled)
8. (Currently amended) A method of treating a subject at risk of atherothrombosis and/or plaque rupture~~[[,]]~~ comprising administering to said subject a pharmaceutical composition comprising an effective amount of pooled immunoglobulins with the

capacity to inhibit antibodies binding to Annexin V or a purified subfraction of pooled immunoglobulins with the capacity to promote binding of Annexin V to endothelium.

9. (Currently amended) ~~[[A]]The method according to claim 8, or a use according to claim 6 of claim 7, where~~wherein the subject at risk is a systemic lupus erythematosus (SLE) patient.
10. (Currently amended) ~~A use or method according to any one of the preceding claims for preventing atherothrombosis and/or plaque rupture in a human~~The method according to claim 4, wherein said subject exhibits vulnerable plaques.
11. (Currently amended) ~~A use of~~The method according to any one of the preceding claims for preventing atherothrombosis and/or plaque rupture in a patient withclaim 8, wherein said subject exhibits vulnerable plaques.
12. (New) The pharmaceutical composition of claim 6, wherein the immunoglobulins with the capacity to promote binding of Annexin V to endothelium are antibodies that can decrease the inhibitory effect of serum with a high antiphospholipid antibody titre on the binding of Annexin V to endothelial cells, anti-aPAF antibodies, anti-IgG antibodies and/or an intravenous immunoglobulin preparation from pooled plasma.
13. (New) The method of claim 8, wherein the immunoglobulins with the capacity to promote binding of Annexin V to endothelium are antibodies that can decrease the inhibitory effect of serum with a high antiphospholipid antibody titre on the binding of Annexin V to endothelial cells, anti-aPAF antibodies, anti-IgG antibodies and/or an intravenous immunoglobulin preparation from pooled plasma.